Literature DB >> 3012625

Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689).

J S Rasey, K A Krohn, Z Grunbaum, A M Spence, T W Menard, R A Wade.   

Abstract

35S- and 3H-labeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689) have been synthesized in our laboratory and used to study organ and cellular level distribution in C3H/Km mice bearing RIF-1 tumors. Tissue biodistributions obtained with 35S-WR-3689 showed that blood levels peak at 15 min postinjection and decline gradually over 60 min. At 30 min after drug injection the highest uptake is in kidney and submandibular salivary gland, with lowest levels in brain and moderate to low levels in the RIF-1 tumor, comparable to levels in skin and muscle. High resolution diffusible substance autoradiography with 3H-WR-3689 reveals a homogenous distribution of label over cells in liver and lung and nonuniform distribution of silver grains over the cytoplasm of cells in the kidney cortex, parotid and submandibular salivary glands, and small intestine. There are no indications of preferential nuclear location of label from protective drug in any tissue. Correlations of biodistribution and autoradiography data with measures of radioprotection in different tissues will be useful in interpreting mechanisms of radioprotection with this phosphorothioate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012625

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  2 in total

Review 1.  Mass spectrometry-based tissue imaging of small molecules.

Authors:  Carly N Ferguson; Joseph W M Fowler; Jonathan F Waxer; Richard A Gatti; Joseph A Loo
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

2.  Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.

Authors:  K H Bohuslavizki; S Klutmann; C Bleckmann; W Brenner; S Lassmann; J Mester; E Henze; M Clausen
Journal:  Strahlenther Onkol       Date:  1999-02       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.